# Corcept Therapeutics Inc. (CORT) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/CORT
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 8, 2026

Corcept Therapeutics Inc. (CORT) last closed at $110.77, near the top of its 52-week range of $28.66–$122.21. Composite market sentiment across 1 analysis is neutral (-2 on a −100 to +100 scale), as of Aug 8, 2026.

## What the data says

Corcept closes at $110.77, near the upper end of a 52-week band that runs from $28.66 to $122.21. That range is unusually wide — the low sits roughly a quarter of the high — so the last year has involved a large repricing rather than steady drift, and the current level sits closer to where the stock has recently traded at its strongest than to where it began the span.

The market is valuing the business at about $12.0 billion, or roughly 236 times trailing earnings and 16.9 times book value. That trailing multiple sits far above the forward multiple of about 24.5, a gap that reflects expected earnings well above what the last twelve months produced. The underlying profitability is thinner than the multiple alone would imply: net margin is about 6.6%, with revenue growing roughly 31.7% year over year. Beta of 0.455 means the shares have historically moved less than half as much as the broad market, so the price swings here have come more from company-specific developments than from market direction.

The news flow is heavily company-specific and split between two distinct threads. April 2026 brought a dense cluster of law-firm notices tied to a securities class action, with several referencing an April 21 lead plaintiff deadline and one connecting the case to a relacorilant setback. A July 2026 item covers insider share sales following an FDA approval and a $1.05 billion outlook. Only one recent headline is sector-level rather than company-level: a June 2026 comparison of pharmaceutical and biotech ETFs.

## About Corcept Therapeutics Inc.

Corcept Therapeutics is a biopharmaceutical company that discovers and develops medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its work centers on modulating the effects of cortisol, the hormone implicated in a range of serious conditions. The company's marketed product, Korlym, is an oral treatment for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who also have type 2 diabetes or glucose intolerance and who have not responded to surgery or are not surgical candidates.

Beyond Korlym, Corcept has developed a portfolio of proprietary selective cortisol modulators, including relacorilant for patients with hypercortisolism, miricorilant in metabolic dysfunction-associated steatohepatitis, dazucorilant in amyotrophic lateral sclerosis (ALS), and nenocorilant. The company was incorporated in 1998 and is headquartered in Redwood City, California.

## Company profile

- Symbol: CORT
- Exchange: NASDAQ
- Security type: Stock
- Sector: Healthcare
- Industry: Biotechnology
- Composite sentiment: neutral (-2 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $11.97B |
| Enterprise value | $11.68B |
| Trailing P/E | 235.68 |
| Forward P/E | 24.52 |
| Price to book | 16.94 |
| Price to sales | 14.41 |
| Beta | 0.46 |
| Net margin | 6.64% |
| Revenue growth | 31.70% |
| Earnings growth | 24.10% |
| 52-week high | $122.21 |
| 52-week low | $28.66 |
| Average volume | 1.17M |

## Related stocks

- [BMY](https://synoptiv.com/stock/BMY)
- [RPRX](https://synoptiv.com/stock/RPRX)
- [ZTS](https://synoptiv.com/stock/ZTS)
- [VTRS](https://synoptiv.com/stock/VTRS)
- [ELAN](https://synoptiv.com/stock/ELAN)
- [AXSM](https://synoptiv.com/stock/AXSM)
- [CRNX](https://synoptiv.com/stock/CRNX)
- [LQDA](https://synoptiv.com/stock/LQDA)
- [BLTE](https://synoptiv.com/stock/BLTE)
- [LLY](https://synoptiv.com/stock/LLY)

## Recent news

- [Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales](https://finance.yahoo.com/markets/stocks/articles/corcept-therapeutics-cort-stock-may-221149797.html) — Aug 7, 2026
- [Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation](https://www.barchart.com/story/news/3643232/corcept-therapeutics-stock-shines-at-new-all-time-highs-despite-its-valuation) — Aug 5, 2026
- [What IJR's Own History Says About Its Price Today](https://www.trefis.com/articles/609832/what-ijrs-own-history-says-about-its-price-today/2026-08-04) — Aug 4, 2026
- [John Hussman's Top Q2 2026 Move: Exiting Corcept Therapeutics Inc at a -1.1% Portfolio Impact](https://finance.yahoo.com/markets/stocks/articles/john-hussmans-top-q2-2026-000117416.html) — Aug 3, 2026
- [Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It](https://seekingalpha.com/article/4928743-corcept-therapeutics-lifyorli-is-a-blockbuster-but-the-valuation-already-knows-it) — Jul 31, 2026
- [A spot is opening up in the S&P 500, and these stocks are top candidates to fill the void](https://www.marketwatch.com/story/a-spot-is-opening-up-in-the-s-p-500-and-these-stocks-are-top-candidates-to-fill-the-void-5e72dd5d?mod=mw_FV) — Jul 31, 2026
- [These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months](https://stocktwits.com/news-articles/markets/equity/cort-stock-52-week-high-q2-results-anika-therapeutics-outlook/cZN5JErRJ2c) — Jul 30, 2026
- [CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised](https://finance.yahoo.com/healthcare/articles/cort-q2-earnings-revenues-beat-160200729.html) — Jul 30, 2026
- [Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165](https://www.benzinga.com/news/26/07/60814998/piper-sandler-reiterates-overweight-corcept-therapeutics-raises-price-target-165) — Jul 30, 2026
- [These 2 Biotech Stocks Hit New 52-Week Highs Today And CORT Clocked Its Best Day In Nearly 16 Months](https://finance.yahoo.com/m/89534209-7fce-37c4-bb20-d90f0b072350/these-2-biotech-stocks-hit.html) — Jul 30, 2026

## Frequently asked questions

### What is the current market sentiment for CORT?

As of Aug 8, 2026, Corcept Therapeutics Inc. (CORT) carries neutral (-2 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has CORT stock been performing?

Corcept Therapeutics Inc. last closed at $110.77, near the top of its 52-week range of $28.66–$122.21.

### What is CORT's market cap and valuation?

Corcept Therapeutics Inc. has a market capitalization of about $11.97B, a trailing P/E of 235.7.

### What sector is CORT in, and who are its competitors?

Corcept Therapeutics Inc. operates in the Healthcare sector, specifically Biotechnology. Comparable companies include BMY, RPRX, ZTS, VTRS, ELAN.

### Where can I find a full analysis of CORT?

The full CORT report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/CORT/v/1) (account and access required)